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ABSTRACT
Purpose: To evaluate the potential benefit of histamine combined with melphalan in the isolated limb perfusion (ILP) as an
alternative to TNF-alfa and melphalan combination, for the treatment of irressectable soft tissue sarcomas of the limbs in
Brown Norway (BN) rats. Methods: 20 BN rats had small fragments of syngeneic BN-175 fibosarcoma inserted on the right
hind limb. In 7-10 days the tumor reached a median diameter of 12-15 mm and they were randomly divided in four groups
(sham, melphalan, histamine and escalating doses of histamine combined to melphalan) being submitted to experimental
ILP for 30 minutes. Tumors were measured daily with a caliper and the volume was calculated. Results: Response curves
showed a significant effect of the combination of histamine 200 mg/mL with melphalan, with 66% overall response,
including 33% complete responses (p< 0.01). There were no systemic collateral effects and locally only mild temporary
edema was observed for some animals treated with histamine. Conclusion: Histamine combined with melphalan had a
promising effect in the ILP warranting future studies to better explore the mechanism of action as well as its potential use
in organ perfusion.
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RESUMO
Objetivo: Avaliar o potencial benéfico da histamina combinada ao melfalano, na perfusão de membro isolado (PMI), como
alternativa à combinação TNF-alfa mais melfalano, no tratamento de sarcomas de partes moles irressecaveis em extremidades,
em ratos de linhagem Brown Norway (BN). Métodos: 20 ratos BN foram submetidos a implantação de fragmentos de
fibrosarcoma singênico BN-175 na pata traseira direita. Em cerca de 7-10 dias o tumor atingiu um diâmetro médio de 12-15
mm e foram aleatóriamente divididos em quatro grupos (controle, melfalano, histamina em doses progessivas combinada
ao melfalano e histamina) sendo submetidos a PMI experimental por 30 minutos. Os tumores foram então medidos diariamente
com o uso de paquímetro e o  volume tumoral calculado. Resultados: As curvas de resposta mostram um efeito significativo
da combinação de Histamina na concentração de 200 mg/mL ao melfalano, com 66% de resposta global incluindo 33% de
respostas completas (p < 0.01). Não houve efeitos colaterais sistêmicos e localmente apenas edema leve e transitório nos
animais tratados com histamine. Conclusão: A histamina em combinação com o melfalano apresenta um efeito promissor
na PMI garantindo maiores investigações do seu mecanismo de ação e do seu potencial uso na perfusão de órgãos.
Descritores: Sarcomas. Modelos experimentais. Tratamento regional. Histamina
Introduction
Soft tissue sarcomas (STS) are tumors of mesenchymal
origin and account for approximately 1% of all adult
malignant tumors in the USA1 and for 5,500 new cases per
year in Brazil. Circa 60% of them occur in the extremities and
are often large at first diagnosis with an aggressive local
growth and propensity for hematogenic spread so that half
of the patients will die of disseminated disease. Limb
amputation has not shown any benefit in overall survival,
thus conservative approaches capable of preserving
extremities and maintaining good function are a corner stone
of patient approach2. Isolated limb perfusion (ILP) was first
described as a treatment modality for in transit metastasis
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of melanoma restricted to the limbs, based on the delivery
of high doses of cytostatic drugs (mainly melphalan for the
best results and least morbidity) to a tumor-bearing
extremity, surgically and temporarily isolated from the
systemic circulation by the use of a heart-lung machine3, 4, 5.
The rational of the method is that in the ILP setting
locoregional concentrations of melphalan, 15 to 20 times
higher than after systemic administration, can be achieved
without systemic toxicity 6, 7. Complete responses (CR)
reached up to 50%8 in melanoma patients while in soft tissue
sarcomas responses were as poor as 20% Overall
Responses (OR), including partial and complete9.  The
combination of TNF-alpha to melphalan brought a new
perspective to this modality of treatment with a limb salvage
index of 71% and 76% of OR 6.  In spite of these excellent
results, circa 30% of the patients will not respond to
standard treatment and might require a limb amputation.
Furthermore, TNF-alpha is still not available in many
countries both for regulatory and economic reasons
restricting the use of this limb salvage procedure to the
treatment of in transit metastasis of melanoma. This is still
the situation in Brazil, for example, in spite of an experience
of more than 10 years with ILP 5. Searching for an alternative
we evaluated the potential benefit of Histamine (Hi), an
inflammatory mediator formed and stored mainly in the
granules of mast cells and basophils but also in cells of the
epidermis, gastric mucosa, and neurons of the central
nervous system as well as in cells in regenerating or rapidly
growing tissues. Its classical effect on fine vessels is the
formation of edema by an increase in the flow of lymph and
its protein content to the extracellular space and also the
formation of gaps between endothelial cells, increasing
transcapillary vesicular transport10. Potentially, this could
result in an enhanced drug uptake in the tumor and thus
lead to improved antitumor responses. We used an
established experimental model11, which closely mimics the
clinical ILP, in order to evaluate the potential synergy of Hi
with melphalan, improving tumor response in soft tissue
sarcomas.
Methods
The studies were done at the Laboratory for
Experimental Surgical Oncology of the Department of
Surgical Oncology of the Erasmus University Medical Center
in Rotterdam, the Netherlands. They were in accordance
with the Dutch Animal Experimentation Act (1977) and the
Guidelines on the protection of experimental animals of the
European Community council (1986). Furthermore, the
specific protocols for this study were approved by the
Erasmus University Rotterdam Animal Committee – the
Netherlands. Male inbred Brown Norway (BN) rats were
obtained from Harlan-CPB (Austerlitz, the Netherlands),
weighing 250-300 g and were fed a standard laboratory diet
ad libitum (Hope Farms Woerden, the Netherlands). Frozen
small fragments (3 mm) of the syngeneic BN-175 sarcoma
maintained in liquid nitrogen under -800C were quickly
defrost and inserted subcutaneously in the dorsum of BN
rats for expansion. Upon a diameter of around 3 cm the
animal was killed under anesthesia by cervical dislocation
and the tumor excised and then divided in small fragments
of viable tumor tissue of circa 3 mm diameter. Next, these
small fragments were inserted subcutaneously in the right
hind leg of the animals in groups no bigger than 15 animals.
For this, a little incision on the skin above the ankle was
made, with the dissection of the tissue and its closure with
clip12. Tumor growth was evaluated by daily measures of
the main diameters with a caliper and the calculation of the
volume using the formula 0.4 (A2 x B) (where B represents
the largest tumor diameter and A is the diameter
perpendicular to it). When tumor diameter exceeded 25 mm
or at the end of the experiment rats were killed by cervical
dislocation, under anesthesia. In seven to ten days, the
diameter reached values between 12-15 mm and the tumors
were amenable to the procedure12 (Figure 1a). Under
anesthesia, using 0.5 ìg/kg intraperitoneal ketamine and 0.5
ìg/kg intramuscular hypnomidate, the rats were fixed in
dorsal position to the operating table with adhesive tape.
The inguinal vessels (Figure 1b) were reached through an
incision parallel to the inguinal ligament with the use of a
surgical microscope. Before manipulating the vessels, 50
IU of heparin were administered in bolus by the penile vein.
Next, the femoral artery and vein were canulated with silicon
tubes measuring 0.012 inches internal diameter and 0.025 of
external diameter and 0.025 and 0.047 inches, respectively
(Dow Corning, Michigan, USA). The tubes were connected
via a roller pump to an oxygenated reservoir containing 5
mL perfusate. A groin tourniquet occluded collateral vessels,
warranting a proper isolation of the limb, controlled by the
maintenance of a stable volume (Figures 1c and d).
The limb was maintained at a temperature of 38oC by
the use of a water mattress around the limb covered by an
aluminum foil. A thermometer controlled the temperature
during the whole procedure that lasted 30 minutes.  At the
end of the ILP a washout was done with 2 mL of oxygenated
haemaccel. Next the cannulas were taken out and the vessels
ligated. Skin was closed with continuous suture and the
animal was put under a heating light till complete recovery,
in order to avoid hypothermia. According to the group the
animal was randomized to, the 5 mL perfusate would consist
of: 1) haemaccel alone (Boehring Pharma, Amsterdam, the
Netherlands); 2) haemaccel plus 40 mg melphalan (AlkeranÒ
Wellcome, Beckenham, United Kingdom); 3) haemaccel, 40
mg melphalan and escalating doses of Hi (kindly provided
by Maxim Pharmaceuticals Inc., San Diego, CA), ranging
from 100 to 2000 mg or 4) haemaccel plus 1000 mg Hi. Tumor
dimensions were measured every day for volume evaluation.
Response was classified as: progressive disease (PD)
increase of more than 25%; no change (NC) volume kept in
the range of –25% to +25% of the initial one; partial
remission (PR) decrease between  –25% and –90%, or
complete response (CR) final tumor volume less than 10%
of initial, as compared to volume on day nine. Limb function
was clinically observed as the ability to walk and stand on
the perfused limb after ILP. On a scale from grade 0 to 2,
grade 0 is a severely impaired function where the rat drags
its hind limb; 1, a slightly impaired function (can not use it
in a normal way, but stand on it); finally 2 is an intact function
(normal walking and standing pattern). Tumor growth curves
were plotted as means and standard deviation (SD) of the
data from all animals. Statistical evaluation was done by
repeated measures ANOVA analyses of the three most
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representative days: 4, 8 and 10 using SAS Software Release
8.2 for Windows 2000 (SAS Institute Inc., Cary, NC, USA)
using PROC MIXED. Main effects of treatment and day
(three levels: day 4, 8 and 10) were included in the models
as was the interaction between treatment and day. For days
where response was statistically significant, interaction
terms were further investigated by testing for differences
following treatment on that day.
Results
Tumors grew exponentially in the BN rats after control
ILP, as expected. The use of Hi plus melphalan led to tumor
regression in 66% of the treated animals, including 33%
with no palpable tumors (CR), approximately 10 days after
treatment (p<0.01) (Fig 2 and 3). This effect was only
observed when Hi dose reached 1,000 mg (concentration of
200 mg/mL) and would not improve even after doubling the
concentration to 400 mg/mL. It is also of note that Hi alone
had an effect very similar to melphalan alone, when the
curves are evaluated together (Fig 3). Yet, looking closer at
the pattern of response the first resulted in a reduced or
stable tumor growth rate with 50% SD while the second led
to 17% PR. Perfusion with Hi, either alone or combined with
melphalan, did not cause systemic side effects. As for
regional toxicity only some transient edema after Hi ILP,
both with and without melphalan, was observed leading to
temporary grade 1 toxicity in two rats for each group.
FIGURE 1 - a) Brown Norway (BN) rat showing the
tumor amenable to experimental ILP (red
arrow); b) close up view of the inguinal
incision showing the femoral artery and
vein; c) eye-bird view of the experimental
ILP showing the dorsal position of the
animal, fixed with adhesive tapes to the
operating table and the cotton swab
combined to a rubber band, used as a
tourniquet; d) wider view of the surgical
table with the operating microscope, the
pumping machine (green) and the heater
(brown).
FIGURE 2 - Tumor volume on days 4, 8 and 10
according to the ILP treatment
administered. Tumors were measured
daily with a caliper and volume was
calculated using the formula 0.4 (A2 x
B) (where B represents the largest tumor
diameter and A is the diameter
perpendicular to it).
FIGURE 3 - Tumor response after experimental ILP
with Sham, Hi 1000 ug, Hi 500, 1000 and
2000 ug combined to melphalan. Mean
tumor volumes with standard deviation.
P < 0.01 for Hi 1000 ug + melphalan on
day 8 and 10 as compared to Sham.
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Discussion
First of all is important to stress that the experimental
model of ILP requires a learning curve before obtaining
trustable results. One of the main issues playing a role on
quality is the time taken between anesthesia and the isolation
and canulation of the femoral vessels. This might determine
a significant leakage and, in this case just opposite to what
is seen in the clinical setting there is not much to do besides
reducing flow speed. Once more than 4 mL is lost the limb
will present such a significant edema in the post-operative
period that further evaluation of the treatment administered
is prevented. Also the morbidity in these situations would
result in such a suffering of the subject that, according to
ethical recommendations, it would be better to sacrifice the
animal. We showed for the first time the promising activity
of Histamine plus melphalan in ILP, for the treatment of soft
tissue sarcomas. Among the advantages of Hi as compared
to TNF-alpha we could include its pharmacokinetics with a
short half-life in the serum of only 0.35 minutes against 20
minutes for TNF-a13. Hi is metabolized through two major
pathways in man: the more important involves ring
methylation and is catalyzed by the enzyme histamine-N-
methyltransferase, which is widely distributed. Most of the
product, N-methylhistamine is converted by monoamine
oxidase (MAO) to N-methyl imidazole acetic acid.
Alternatively Hi undergoes oxidative deamination
catalyzed mainly by the nonspecific enzyme diamine oxidase
(DAO). The products are imidazole acetic acid and its
riboside. The metabolites with little or no activity are
excreted in the urine10. Although these data come from
studies with lower dosages or endogenous Hi they describe
a widely distributed and fast metabolizing system, which
would suggest a potentially safer drug in case of some
leakage during the ILP. Furthermore, our finding opens new
possibilities of application in potentially less well-isolated
settings as for example the isolated liver perfusion.  Still,
more studies on the pharmacokinetics for the higher doses
and evaluation in the clinical setting are mandatory for the
clinical translation of Hi.
Another advantage, mainly for exploring its use in
organ perfusion, would be its lack of toxicity towards the
liver as compared to TNF-a, which exhibits a  small window
for dosage increase.
Conclusion
 Hi plus melphalan in the ILP seems a promising
alternative and worth being evaluated in the clinical setting.
Further studies are required to better detail its mechanism
of action.
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